EVO (Evotec SE) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


EVO Evotec SE EVO
64 GF Score
Price $2.74
GF Value $4.27
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Evotec SE Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Evotec SE's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

EVO vs ZTS, UTHR, VTRS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evotec SE Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Evotec SE's Margin of Safety % (DCF Earnings Based) falls into.


EVO
64GF Score
Evotec SE EVO
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Evotec SE (EVO) Overvalued in 2026?

Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued. The current stock price of $2.74 is trading 35.8% below its estimated GF Value™ of $4.27. GuruFocus considers Evotec SE to be Possible Value Trap.

Key valuation signals for EVO:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $4.27 vs. price of $2.74 (35.8% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the EVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evotec SE Business Description

Address Essener Bogen 7, 22419 Hamburg, Hamburg, DEU, 22419
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
64GF Score

Get the complete analysis for EVO

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.74
Price
$4.27
GF Value